Toxic astrocyte fats that harm retinal nerve cells in glaucoma
Neurotoxicity of Reactive Astrocyte-secreted Lipids in Neurodegenerative Disease
This work looks at whether fatty molecules released by reactive support cells called astrocytes cause retinal nerve cells to die in glaucoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11262202 on NIH RePORTER |
What this research studies
The team examines human postmortem tissue, lab-grown nerve cells, and animal models of glaucoma to trace harmful lipid production from reactive astrocytes. They identify long-chain free fatty acids secreted by these astrocytes that kill retinal ganglion cells in vitro and in vivo. The investigators test whether blocking the enzyme Elovl1 in astrocytes prevents production of the toxic lipids and preserves neuron numbers and function. Results could point to new ways to protect retinal neurons before they are lost.
Who could benefit from this research
Good fit: People with glaucoma or those at high risk of retinal ganglion cell loss would be the most relevant group, especially if they can donate tissue or be considered for future clinical trials.
Not a fit: Patients whose vision loss is already advanced with widespread, irreversible neuron loss or those with eye conditions unrelated to retinal ganglion cell degeneration may not benefit.
Why it matters
Potential benefit: If successful, this work could lead to therapies that stop astrocyte-produced toxic lipids and help preserve vision by saving retinal ganglion cells.
How similar studies have performed: Previous lab studies have shown that preventing formation of neurotoxic reactive astrocytes can spare neurons, while targeting the specific lipid-producing enzyme Elovl1 is a newer and less-tested approach.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Liddelow, Shane — New York University School of Medicine
- Study coordinator: Liddelow, Shane
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.